Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.58 |
| ▸ | HTR2A | P28223 | 13/20 | 0.58 |
| ▸ | HTR2B | P41595 | 3/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18926931 | 0.87 | RPS6KA5 (0.47) | HTR2CHTR2AHTR2BNR3C1NR3C2 | |
| SCHEMBL12640059 | 0.78 | RPS6KA5 (0.52) | NR3C1NR3C2RPS6KA5METP2RX7 | |
| SCHEMBL14408911 | 0.77 | APAF1 (0.63) | — | |
| SCHEMBL14409582 | 0.75 | MET (0.52) | RPS6KA5METP2RX7 | |
| SCHEMBL25818055 | 0.74 | HTR2C (0.56) | HTR2CHTR2AHTR2B | |
| SCHEMBL25818081 | 0.74 | HTR2C (0.65) | HTR2CHTR2AHTR2BP2RX7 | |
| SCHEMBL31609660 | 0.74 | RPS6KA5 (0.52) | NR3C1NR3C2RPS6KA5METP2RX7 | |
| SCHEMBL6603614 | 0.74 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL6605040 | 0.74 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL6604307 | 0.74 | HTR2C (1.00) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | ABL1, CRKL, MGMT | HTR2C 775/4885HTR2A 2609/4885HTR2B 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.